WARRINGTON, Pa., Oct. 29, 2008 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that results from pre-clinical studies regarding its novel KL-4 surfactant technology were presented at two key medical congresses in October. Pre-clinical data supporting the use of KL-4 surfactant in the treatment of Cystic Fibrosis were presented at the International Society for Aerosols in Medicine (ISAM)/University of North Carolina (UNC) Symposium on mucociliary clearance. Additionally, pre-clinical Surfaxin(r) and Aerosurf(tm) data were presented at the European Academy of Pediatrics (EAP), a prestigious pediatric congress attended by 2,500 pediatric clinicians, researchers, and nurses from over 85 countries.
